Pharmaceutical Preparations · DE · CIK 1750284
Olema develops targeted therapies for breast cancer, including its lead candidate palazestrant
Comparable business profile · signals at a glance
In the 90 days to Mar 4, 2026: 6 sold $24.4M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Mitchell ShawnteCHIEF LEGAL OFFICER | Sell | 24,767 | $24.25 | $601K |
| Mar 4, 2026 | Mitchell ShawnteCHIEF LEGAL OFFICER | Sell | 233 | $24.69 | $6K |
| Mar 3, 2026 | Mitchell ShawnteCHIEF LEGAL OFFICER | Sell | 15,000 | $23.01 | $345K |
| Jan 20, 2026 | Harmon CyrusDirector | Sell | 10,000 | $26.88 | $269K |
| Jan 15, 2026 | Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF. | Sell | 100,000 | $28.73 | $2.9M |
| Jan 14, 2026 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | Sell | 35,003 | $28.99 | $1.0M |
| Jan 14, 2026 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | Sell | 14,997 | $28.60 | $429K |
| Jan 14, 2026 | Harmon CyrusDirector | Sell | 3,489 | $29.12 | $102K |
| Jan 13, 2026 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | Sell | 49,800 | $27.60 | $1.4M |
| Jan 13, 2026 | Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF. | Sell | 3,822 | $28.01 | $107K |
| Jan 13, 2026 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | Sell | 200 | $28.49 | $6K |
| Jan 12, 2026 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | Sell | 10,000 | $28.34 | $283K |
| Dec 23, 2025 | Zojwalla NaseemChief Medical Officer | Sell | 99,509 | $27.66 | $2.8M |
| Dec 22, 2025 | Zojwalla NaseemChief Medical Officer | Sell | 100,000 | $28.04 | $2.8M |
| Dec 22, 2025 | Harmon CyrusDirector | Sell | 2,881 | $28.53 | $82K |
| Dec 19, 2025 | Clark Ian TDirector | Sell | 193,056 | $29.71 | $5.7M |
| Dec 19, 2025 | Zojwalla NaseemChief Medical Officer | Sell | 57,079 | $28.03 | $1.6M |
| Dec 19, 2025 | Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | Sell | 43,729 | $30.40 | $1.3M |
| Dec 19, 2025 | Clark Ian TDirector | Sell | 41,840 | $30.48 | $1.3M |
| Dec 19, 2025 | Clark Ian TDirector | Sell | 29,904 | $28.83 | $862K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.